College of Bioengineering, Chongqing University, Chongqing 400030, China.
Chin Med J (Engl). 2010 Feb 5;123(3):320-5.
A patented remote controlled capsule (RCC) has recently been developed to provide noninvasive drug delivery to selected sites in the human gut that allows assessment of regional gastrointestinal (GI) drug absorption under a normal physiological environment. The objective of this study was to investigate the rate and extent of aminophylline absorption after site-specific delivery of the drug in the GI tract using RCC and a magnetic marker monitoring (MMM) technique.
This study was conducted in twelve healthy male subjects, in a three-treatment, randomized, crossover manner with a 7-day washout. Eligible subjects received a 150 mg aminophylline dose through an oral administration, or via a remote controlled capsule, delivered to the small bowel or ascending colon. MMM was employed to monitor the GI transit of the RCC, and the radio-frequency signal was used to activate capsules at target sites. Blood samples were obtained at regular intervals until 24 hours post dose/activation. Plasma theophylline concentrations were measured by a TDx System Analyzer. A comparison of the PK profile with the oral dosing route of aminophylline was performed after delivery to the small bowel and colon.
The RCC was well tolerated in volunteers. The mean capsule activation time for the small bowel and ascending colon was 2.07 hours and 6.08 hours post dose. Aminophylline had similar absorption profiles from the small bowel compared with the stomach, with an area under the curve (AUC(t)) ratio of 92% vs. the stomach, but a lower absorption profile from the ascending colon, with an AUC(t) ratio of 47.2% vs. the stomach.
The proprietary of the RCC and MMM technique offer the opportunity to obtain data on the intestinal absorption of a drug in humans under noninvasive conditions. Aminophylline is rapidly and efficiently absorbed from the small bowel. While colonic absorption was limited by the poor water condition although effective absorption was observed from the ascending colon. This provides an opportunity for rational development of modified-release formulations as well as alternative dosage forms.
最近开发了一种专利的遥控胶囊(RCC),用于将药物非侵入性地递送到人体肠道的选定部位,以便在正常生理环境下评估区域性胃肠道(GI)药物吸收。本研究的目的是使用 RCC 和磁标记监测(MMM)技术研究药物在胃肠道中特定部位给药后氨茶碱的吸收速度和程度。
本研究在 12 名健康男性志愿者中进行,采用三治疗、随机、交叉设计,洗脱期为 7 天。合格的受试者通过口服或遥控胶囊给予 150mg 氨茶碱剂量,该胶囊递送至小肠或升结肠。MMM 用于监测 RCC 的胃肠道转运,射频信号用于在靶部位激活胶囊。在给药/激活后 24 小时内定期采集血样。采用 TDx 系统分析仪测定血浆茶碱浓度。在递送至小肠和结肠后,将其 PK 曲线与口服氨茶碱的 PK 曲线进行比较。
志愿者对 RCC 耐受良好。给药后 2.07 小时和 6.08 小时,胶囊在小肠和升结肠的平均激活时间。与胃相比,氨茶碱从小肠吸收的吸收谱相似,曲线下面积(AUC(t))比值为 92%,但从升结肠吸收的吸收谱较低,AUC(t)比值为 47.2%。
RCC 和 MMM 技术的专有技术为在非侵入性条件下获得人体肠道药物吸收数据提供了机会。氨茶碱从小肠迅速高效吸收。虽然结肠吸收受到较差的水条件限制,但仍观察到升结肠的有效吸收。这为开发改良释放制剂和替代剂型提供了机会。